131 related articles for article (PubMed ID: 8387177)
1. The case for mitomycin in non-small cell lung cancer.
Spain RC
Oncology; 1993 Apr; 50 Suppl 1():35-50. PubMed ID: 8387177
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
[TBL] [Abstract][Full Text] [Related]
5. Experience with mitomycin in the treatment of non-small cell lung cancer.
Folman RS
Oncology; 1993 Apr; 50 Suppl 1():24-30. PubMed ID: 8387175
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
Ng KK; Kris MG; Ginsberg RJ; Heelan RT; Pisters KM; Miller VA; Grant SC; Bains M; Rusch V; Rosenzweig KE; Martini N
Cancer; 1999 Oct; 86(7):1189-97. PubMed ID: 10506703
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
González Barón M; Feliu J; Espinosa E; García Girón C; Blanco E; Garrido P; Colmenarejo A; Ordóñez A; Moyano A; de la Gándara I
Ann Oncol; 1994 Apr; 5(4):323-7. PubMed ID: 8075028
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
Pisters KM; Kris MG; Gralla RJ; Zaman MB; Heelan RT; Martini N
J Clin Oncol; 1993 Sep; 11(9):1757-62. PubMed ID: 8394881
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
[TBL] [Abstract][Full Text] [Related]
13. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
Riggi M; Ruffie P; Voisin S; Monnet I; de Cremoux H; Saltiel JC; Martin M; Vergne L; Huet J; Cvitkovic E
Eur J Cancer; 1991; 27(10):1238-42. PubMed ID: 1659842
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
15. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel JC; Finkelstein DM; Ettinger DS; Creech RH; Mason BA; Joss RA; Vogl S
J Clin Oncol; 1986 Jan; 4(1):14-22. PubMed ID: 3510278
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long-term follow-up.
Spain RC
Semin Oncol; 1988 Jun; 15(3 Suppl 4):6-15. PubMed ID: 2839905
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
[TBL] [Abstract][Full Text] [Related]
19. [A pilot study of induction chemotherapy with cisplatin, mitomycin C and vindesine for stage III N2 non-small cell lung cancer].
Nishiwaki Y; Nagai K; Kodama T; Nishiyama H; Hojo H; Matsumoto T
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():203-11. PubMed ID: 8007467
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
